ALNY:NGS-Alnylam Pharmaceuticals Inc. (USD)

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing

USD 279.82

Change

+2.39 (+0.86)%

Market Cap

USD 3.92B

Volume

0.87M

Analyst Target

USD 166.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Alnylam Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in developing novel therapeutics based on RNA interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for regulating the expression of specific genes.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-11 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

-11.72 (-2.34%)

USD 121.60B
REGN Regeneron Pharmaceuticals Inc

-4.68 (-0.57%)

USD 92.70B
ARGX argenx NV ADR

+5.01 (+0.85%)

USD 35.78B
BGNE BeiGene Ltd

-11.40 (-5.56%)

USD 22.85B
MRNA Moderna Inc

+0.72 (+1.68%)

USD 21.00B
UTHR United Therapeutics Corporatio..

+0.43 (+0.11%)

USD 16.70B
RPRX Royalty Pharma Plc

-0.36 (-1.37%)

USD 16.11B
INCY Incyte Corporation

-0.95 (-1.17%)

USD 14.67B
SMMT Summit Therapeutics PLC

-1.01 (-4.64%)

USD 13.75B
PCVX Vaxcyte Inc

-4.26 (-4.11%)

USD 13.28B

ETFs Containing ALNY

GNOG:LSE Global X Genomics & Biote.. 6.94 % 0.00 %

-0.16 (-1.22%)

USD 8.22M
GN0M:XETRA Global X Genomics & Biote.. 6.79 % 0.00 %

-0.21 (-1.22%)

USD 7.05M
GNOM:SW Global X Genomics & Biote.. 6.79 % 0.00 %

-0.16 (-1.22%)

USD 5.93M
MSGR 6.64 % 0.00 %

N/A

N/A
CURE:XETRA VanEck Genomics and Healt.. 5.76 % 0.00 %

-0.38 (-1.22%)

N/A
CURG:LSE VanEck Genomics and Healt.. 5.47 % 0.00 %

-0.19 (-1.22%)

USD 5.12M
BIOT:SW L&G Pharma Breakthrough U.. 3.89 % 0.00 %

-0.10 (-1.22%)

N/A
BBH VanEck Biotech ETF 3.71 % 0.35 %

-3.95 (-1.22%)

USD 0.43B
QQQN VictoryShares Nasdaq Next.. 3.68 % 0.00 %

N/A

USD 0.02B
IBBQ Invesco Nasdaq Biotechnol.. 3.49 % 0.00 %

-0.59 (-1.22%)

USD 0.04B
2B70:F iShares NASDAQ US Biotech.. 3.49 % 0.00 %

-0.13 (-1.22%)

USD 0.52B
2B70:XETRA iShares Nasdaq US Biotech.. 3.49 % 0.00 %

-0.14 (-1.22%)

USD 0.52B
BTEC:SW iShares Nasdaq US Biotech.. 3.20 % 0.00 %

-0.12 (-1.22%)

N/A
ETLI:XETRA L&G Pharma Breakthrough U.. 3.00 % 0.00 %

-0.18 (-1.22%)

USD 0.02B
CURE:AU ETFS S&P Biotech ETF 2.62 % 0.00 %

-0.61 (-1.22%)

USD 0.04B
BBP Virtus LifeSci Biotech Pr.. 2.58 % 0.79 %

-2.05 (-1.22%)

USD 0.02B
BIB ProShares Ultra Nasdaq Bi.. 2.57 % 0.95 %

-3.58 (-1.22%)

USD 0.08B
QQQJ Invesco NASDAQ Next Gen 1.. 2.35 % 0.00 %

-0.29 (-1.22%)

USD 0.63B
FHH:CA First Trust AlphaDEX US H.. 2.35 % 0.77 %

+0.10 (+-1.22%)

CAD 0.01B
EQQJ:XETRA Invesco NASDAQ Next Gener.. 2.29 % 0.00 %

-0.11 (-1.22%)

USD 0.05B
FXH First Trust Health Care A.. 2.25 % 0.63 %

-1.57 (-1.22%)

USD 1.19B
EQJS:LSE Invesco NASDAQ Next Gener.. 2.18 % 0.00 %

+7.25 (+-1.22%)

USD 0.05B
JNDQ:AU BETAJNDQ ETF UNITS 2.14 % 0.00 %

N/A

N/A
EQQJ:SW Invesco NASDAQ Next Gener.. 2.11 % 0.00 %

-0.30 (-1.22%)

N/A
EQQJ:LSE Invesco NASDAQ Next Gener.. 2.02 % 0.00 %

-0.55 (-1.22%)

N/A
TMFX Motley Fool Next Index ET.. 1.97 % 0.00 %

-0.14 (-1.22%)

USD 0.03B
LABU Direxion Daily S&P Biotec.. 1.48 % 1.14 %

-12.47 (-1.22%)

USD 0.99B
WELP:LSE HAN-GINS Indxx Healthcare.. 1.36 % 0.00 %

-1.45 (-1.22%)

N/A
THNZ:XETRA L&G Global Thematic ESG E.. 0.87 % 0.00 %

-0.10 (-1.22%)

N/A
ETHO Amplify ETF Trust 0.59 % 0.45 %

-0.72 (-1.22%)

USD 0.18B
QDVC:XETRA iShares Edge MSCI USA Siz.. 0.52 % 0.00 %

-0.05 (-1.22%)

USD 0.19B
IUSZ:SW iShares Edge MSCI USA Siz.. 0.52 % 0.00 %

N/A

N/A
IUSF:LSE iShares IV Public Limited.. 0.50 % 0.00 %

+2.25 (+-1.22%)

USD 0.29B
IUSZ:LSE iShares Edge MSCI USA Siz.. 0.50 % 0.00 %

-0.10 (-1.22%)

USD 0.29B
IS3T:XETRA iShares MSCI World Size F.. 0.21 % 0.00 %

-0.40 (-1.22%)

USD 0.24B
IWSZ:SW iShares Edge MSCI World S.. 0.21 % 0.00 %

N/A

USD 0.28B
IWFS:LSE iShares MSCI World Size F.. 0.21 % 0.00 %

-15.50 (-1.22%)

USD 0.28B
IWSZ:LSE iShares IV Public Limited.. 0.21 % 0.00 %

-0.49 (-1.22%)

USD 0.28B
FFTY Innovator IBD® 50 ETF 0.00 % 0.80 %

-0.53 (-1.22%)

N/A
IBB iShares Biotechnology ETF 0.00 % 0.47 %

-3.36 (-1.22%)

USD 7.19B
LABS 0.00 % 0.45 %

N/A

N/A
QRH:CA 0.00 % 1.20 %

N/A

N/A
RBUS 0.00 % 0.30 %

N/A

N/A
GNOM Global X Genomics & Biote.. 0.00 % 0.00 %

-0.32 (-1.22%)

USD 0.08B
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

-0.19 (-1.22%)

N/A
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

-0.09 (-1.22%)

N/A
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

-0.19 (-1.22%)

N/A
XBI SPDR® S&P Biotech ETF 0.00 % 0.35 %

-3.02 (-1.22%)

N/A
ETLI:F Legal & General UCITS ETF.. 0.00 % 0.00 %

+0.23 (+-1.22%)

N/A
ZGEN:CA 0.00 % 0.00 %

N/A

N/A
GERM 0.00 % 0.00 %

N/A

N/A
BMED BlackRock Future Health E.. 0.00 % 0.00 %

-0.29 (-1.22%)

USD 4.07M
FHH-F:CA First Trust AlphaDEX U.S... 0.00 % 0.00 %

N/A

CAD 0.01B
XGES:LSE Xtrackers MSCI Genomic He.. 0.00 % 0.00 %

-0.21 (-1.22%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 46.19% 78% C+ 86% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 46.19% 78% C+ 85% B
Trailing 12 Months  
Capital Gain 69.58% 74% C 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 69.58% 74% C 84% B
Trailing 5 Years  
Capital Gain 208.92% 88% B+ 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 208.92% 88% B+ 91% A-
Average Annual (5 Year Horizon)  
Capital Gain 14.25% 61% D- 67% D+
Dividend Return 14.25% 61% D- 66% D+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 27.36% 89% A- 66% D+
Risk Adjusted Return 52.08% 95% A 79% B-
Market Capitalization 3.92B 100% F 97% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A
Price/Book Ratio 1,105.99 0% 0%
Price / Cash Flow Ratio 343.55 1% 1%
Price/Free Cash Flow Ratio 204.85 1% 2%
Management Effectiveness  
Return on Equity -1,500.66% 5% 2%
Return on Invested Capital -34.83% 70% 27%
Return on Assets -2.92% 93% 46%
Debt to Equity Ratio -462.63% 98% 98%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.